An additional refinement is major analyst jockeys on these volatile growthies use a dividend discount model which gives weight to the negative impact of drug patent expirations 5 to 10 years out.
We believe, at present, the stock is trading at a discount to its fundamental valuation due to the negative sentiment surrounding the stock following the recent earnings release.